Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sahin, M.
Right arrow Articles by Riviello, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahin, M.
Right arrow Articles by Riviello, J. J., Jr.
Related Collections
Right arrow All Pediatric
Right arrow Status epilepticus

Neurology 2003;61:398-401
© 2003 American Academy of Neurology
Brief Communications

Prolonged treatment for acute symptomatic refractory status epilepticus

Outcome in children

Mustafa Sahin, MD PhD, Caroline C. Menache, MD, Gregory L. Holmes, MD and James J. Riviello, Jr., MD

From the Division of Epilepsy and Clinical Neurophysiology and the Critical Care Neurology Service, Department of Neurology, Children’s Hospital, and Department of Neurology, Harvard Medical School, Boston, MA.

Address correspondence and reprint requests to Dr. J.J. Riviello, Jr., Children’s Hospital, 300 Longwood Ave., Boston, MA 02115; e-mail: james.riviello{at}tch.harvard.edu

High-dose suppressive therapy (HDST) is used to treat refractory status epilepticus (RSE). Prolonged therapy is required in some cases, and prognosis is important in making therapeutic decisions. The authors therefore studied the long-term outcome in previously normal children who survived prolonged HDST for acute symptomatic RSE. All have intractable epilepsy, and none returned to baseline.




This article has been cited by other articles:


Home page
 J Intensive Care MedHome page
D. J. Costello and A. J. Cole
Treatment of Acute Seizures and Status Epilepticus
J Intensive Care Med, November 1, 2007; 22(6): 319 - 347.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
I. S. Mohamed, H. Otsubo, K. Imai, M. Shroff, R. Sharma, S. H. Chuang, E. Donner, J. Drake, and O. C. Snead III
Surgical Treatment for Acute Symptomatic Refractory Status Epilepticus: A Case Report
J Child Neurol, April 1, 2007; 22(4): 435 - 439.
[Abstract] [PDF]

Home page
 NeurologyHome page
N. F. Schor and J. J. Riviello Jr
Treatment with propofol: The new status quo for status epilepticus?
Neurology, August 23, 2005; 65(4): 506 - 507.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. Alexopoulos, D. K. Lachhwani, A. Gupta, P. Kotagal, A. M. Harrison, W. Bingaman, and E. Wyllie
Resective surgery to treat refractory status epilepticus in children with focal epileptogenesis
Neurology, February 8, 2005; 64(3): 567 - 570.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
J. J. Riviello Jr
Pharmacology Review: Drug Therapy for Neonatal Seizures: Part 2
NeoReviews, June 1, 2004; 5(6): e262 - e268.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.